Table 4:
Association between statin use and risk of ovarian cancer among participants with and without hypercholesterolemia, hypertension, coronary heart disease, obesity, diabetes, smoking, or medication use.
| Controls |
Cases |
Adjusted* | ||||
|---|---|---|---|---|---|---|
| Variable | Non-users N (%) |
Statin users N (%) |
Non-users N (%) |
Statin users N (%) |
OR (95% CI) for ovarian cancer risk |
P Int |
| Hypercholesterolemia/atherosclerosis | ||||||
| No | 1763 (99) | 22 (1) | 1762 (99) | 22 (1) | 0.87 (0.47 - 1.63) | |
| Yes | 92 (29) | 223 (71) | 90 (35) | 166 (65) | 0.71 (0.48 - 1.06) | 0.52 |
| Hypertension | ||||||
| No | 1604 (93) | 124 (7) | 1592 (94) | 92 (6) | 0.63 (0.47 - 0.86) | |
| Yes | 251 (67) | 121 (33) | 260 (73) | 96 (27) | 0.76 (0.53 - 1.08) | 0.77 |
| Coronary heart disease | ||||||
| No | 1815 (90) | 202 (10) | 1799 (92) | 157 (8) | 0.68 (0.53 - 0.86) | |
| Yes | 40 (48) | 43 (52) | 53 (63) | 31 (37) | 0.54 (0.27 - 1.09) | 0.48 |
| Obesity | ||||||
| No | 1525 (90) | 177 (10) | 1466 (93) | 114 (7) | 0.56 (0.43 - 0.74) | |
| Yes | 322 (83) | 67 (17) | 384 (84) | 74 (16) | 1.12 (0.75 - 1.69) | 0.06 |
| Diabetes | ||||||
| No | 1798 (89) | 214 (11) | 1798 (92) | 158 (8) | 0.63 (0.50 - 0.80) | |
| Yes | 57 (65) | 31 (350 | 54 (64) | 30 (36) | 1.35 (0.64 - 2.86) | 0.13 |
| Smoking status | ||||||
| Never | 907 (90) | 100 (10) | 873 (91) | 86 (9) | 0.77 (0.55 - 1.08) | |
| Former | 681 (85) | 117 (15) | 647 (89) | 80 (11) | 0.66 (0.47 - 0.92) | |
| Current | 267 (91) | 28 (9) | 332 (94) | 22 (6) | 0.45 (0.24 - 0.86) | 0.46 |
| Aspirin use | ||||||
| No | 1532 (91) | 143 (9) | 1499 (92) | 125 (8) | 0.78 (0.59 - 1.03) | |
| Yes | 323 (76) | 102 (24) | 353 (85) | 63 (15) | 0.55 (0.38 - 0.82) | 0.03 |
| NSAIDS use | ||||||
| No | 1112 (91) | 109 (9) | 1162 (92) | 99 (8) | 0.74 (0.54 - 1.01) | |
| Yes | 743 (85) | 136 (15) | 690 (89) | 89 (11) | 0.65 (0.47 - 0.89) | 0.29 |
| Bisphosphonate use | ||||||
| No | 1800 (89) | 219 (11) | 1807 (92) | 167 (8) | 0.68 (0.54 - 0.85) | |
| Yes | 55 (68) | 26 (32) | 45 (68) | 21 (32) | 0.51 (0.20 - 1.26) | 0.76 |
*
Adjusted for age (continuous), study site (Massachusetts, New Hampshire), study phase (1, 2, 3), BMI (continuous), parity (continuous), educational status (≤12 grade, >12 grade), oral contraceptive use (yes/no), tubal ligation (yes/no), family history of ovarian cancer (yes/no), smoking status (never, former, current smoker), menopausal status and HRT use (premenopausal, postmenopausal no HRT use, postmenopausal and used HRT).